INDUSTRY BRIEF: Trump eyes curbs on Chinese drugs, drawing industry pushback
The administration of U.S. President Donald Trump is weighing restrictions on the import of drugs and experimental therapies from China, a move that could disrupt the U.S. pharmaceutical industry and…
BRIEF: Legend Biotech considers second listing outside U.S.
Cancer treatment maker Legend Biotech Corp. (LEGN.US) is weighing a second listing to complement its existing one in the U.S., with possible venues including Hong Kong, Singapore and London, Bloomberg…
BRIEF: WuXi XDC to raise $348 million via share placements at 4% discount
Contract drug services provider WuXi XDC Cayman Inc. (2268.HK) on Wednesday announced two share placements to raise a combined HK$2.71 billion ($348 million) in new funds. The company plans to…
BRIEF: BrainAurora’s revenue nearly doubles but loss widens in first half of 2025
BrainAurora Medical Technology Ltd. (6681.HK) announced on Thursday that its revenue surged 92.8% year-on-year to 100 million yuan ($14 million) in the first half of this year. But the maker…
BRIEF: Surging drug sales drive Hengrui Pharma’s profit growth
Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) saidon Wednesday that its revenue for the first half of 2025 reached 15.76 billion yuan ($2.19 billion), up 15.9% year-on-year. Its…
BRIEF: Modern Dental’s profit jumps over 30% in first half of 2025
Modern Dental Group Ltd. (3600.HK) said on Thursday it expects to report revenue of HK$1.78 billion ($226 million) to HK$1.85 billion for the first half year, up 4.3% to 8.7%…
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
Recent Articles
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
- Will Trump’s drug order put the brakes on China’s overseas pharma drive?
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- RNA drug developer Ribo Life targets fresh funding channel
-
Zai Lab under pressure over clinical results and rival drugs
9688.HK ZLAB.US
